• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于评估多发性硬化症患者中严重 Covid-19 个体风险的多参数评分。

A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.

机构信息

Department of Health Sciences, University of Genoa, Genoa, Italy.

Department of Health Sciences, University of Genoa, Genoa, Italy.

出版信息

Mult Scler Relat Disord. 2022 Jul;63:103909. doi: 10.1016/j.msard.2022.103909. Epub 2022 May 25.

DOI:10.1016/j.msard.2022.103909
PMID:35675744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9130313/
Abstract

BACKGROUND

Many risk factors for the development of severe forms of Covid-19 have been identified, some applying to the general population and others specific to Multiple Sclerosis (MS) patients. However, a score for quantifying the individual risk of severe Covid-19 in patients with MS is not available. The aim of this study was to construct such score and to evaluate its performance.

METHODS

Data on patients with MS infected with Covid-19 in Italy, Turkey and South America were extracted from the Musc-19 platform. After imputation of missing values, data were separated into training data set (70%) and validation data set (30%). Univariable logistic regression models were performed in the training dataset to identify the main risk factors to be included in the multivariable logistic regression analyses. To select the most relevant variables we applied three different approaches: (1) multivariable stepwise, (2) Lasso regression, (3) Bayesian model averaging. Three scores were defined as the linear combination of the coefficients estimated in the models multiplied by the corresponding value of the variables and higher scores were associated to higher risk of severe Covid-19 course. The performances of the three scores were compared in the validation dataset based on the area under the ROC curve (AUC) and an optimal cut-off was calculated in the training dataset for the score with the best performance. The probability of showing a severe Covid-19 course was calculated based on the score with the best performance.

RESULTS

3852 patients were included in the study (2696 in the training dataset and 1156 in the validation data set). 17% of the patients required hospitalization and risk factors for severe Covid-19 course were older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, progressive MS, longer disease duration, higher Expanded Disability Status Scale, Methylprednisolone use and anti-CD20 treatment. The score with the best performance was the one derived using the Lasso selection approach (AUC= 0.72) and it was built with the following variables: age, sex, country, BMI, presence of comorbidities, EDSS, methylprednisolone use, treatment. An excel spreadsheet to calculate the score and the probability of severe Covid-19 is available at the following link: https://osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580.

CONCLUSIONS

The originality of this study consists in building a useful tool to quantify the individual risk for Covid-19 severity based on patient's characteristics. Due to the modest predictive ability and to the need of external validation, this tool is not ready for being fully used in clinical practice to make important decisions or interventions. However, it can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection (i.e. getting vaccinated against Covid-19, adhering to social distancing, and using of personal protection equipment).

摘要

背景

已经确定了许多导致 COVID-19 严重形式的风险因素,其中一些适用于普通人群,另一些则特定于多发性硬化症 (MS) 患者。然而,目前尚无针对 MS 患者 COVID-19 严重程度个体风险的评分。本研究旨在构建这样的评分,并评估其性能。

方法

从 Musc-19 平台提取了意大利、土耳其和南美洲感染 COVID-19 的 MS 患者的数据。在缺失值插补后,数据分为训练数据集(70%)和验证数据集(30%)。在训练数据集中进行单变量逻辑回归模型,以确定纳入多变量逻辑回归分析的主要风险因素。为了选择最相关的变量,我们应用了三种不同的方法:(1)多变量逐步法,(2)套索回归,(3)贝叶斯平均模型。将三个评分定义为模型中估计的系数乘以变量相应值的线性组合,评分越高,COVID-19 严重程度的风险越高。在验证数据集中基于 ROC 曲线下面积(AUC)比较了三种评分的性能,并在训练数据集中计算了性能最佳评分的最佳截断值。基于性能最佳的评分计算出现 COVID-19 严重程度的概率。

结果

共有 3852 名患者纳入研究(2696 名在训练数据集中,1156 名在验证数据集中)。17%的患者需要住院治疗,COVID-19 严重程度的危险因素包括年龄较大、男性、居住在土耳其或南美洲而非意大利、合并症、进展性 MS、疾病持续时间较长、更高的扩展残疾状态量表、使用甲基强的松龙和抗 CD20 治疗。性能最佳的评分是使用套索选择方法得出的(AUC=0.72),并使用以下变量构建:年龄、性别、国家、BMI、合并症、EDSS、甲基强的松龙使用、治疗。计算评分和 COVID-19 严重程度概率的 Excel 电子表格可在以下链接获得:https://osf.io/ac47u/?view_only=691814d57b564a34b3596e4fcdcf8580。

结论

本研究的新颖之处在于构建了一种有用的工具,可根据患者特征量化 COVID-19 严重程度的个体风险。由于预测能力有限,且需要外部验证,因此该工具尚未准备好在临床实践中全面用于做出重要决策或干预。然而,它可以作为识别高危患者的附加工具,并说服他们采取重要措施预防 COVID-19 感染(即接种 COVID-19 疫苗、遵守社交距离和使用个人防护设备)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/9130313/f0952a7068d4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/9130313/f0952a7068d4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c428/9130313/f0952a7068d4/gr1_lrg.jpg

相似文献

1
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.一种用于评估多发性硬化症患者中严重 Covid-19 个体风险的多参数评分。
Mult Scler Relat Disord. 2022 Jul;63:103909. doi: 10.1016/j.msard.2022.103909. Epub 2022 May 25.
2
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis.多发性硬化症患者队列中,遵守社交距离和使用个人防护设备与 SARS-CoV-2 感染风险的关系。
Mult Scler Relat Disord. 2020 Oct;45:102359. doi: 10.1016/j.msard.2020.102359. Epub 2020 Jul 3.
3
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.多发性硬化症患者感染 COVID-19 的风险:一项病例对照研究。
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.
4
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.COVID-19 严重程度在多发性硬化症中的表现:将数据置于具体情境中。
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1). doi: 10.1212/NXI.0000000000001105. Print 2022 Jan.
5
Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.多发性硬化症患者 COVID-19 的可改变风险因素:单中心病例对照研究。
J Neurol. 2023 Apr;270(4):1835-1842. doi: 10.1007/s00415-023-11618-0. Epub 2023 Feb 16.
6
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.多发性硬化症、视神经脊髓炎谱系疾病和 COVID-19:捷克的大流行之年。
Mult Scler Relat Disord. 2021 Sep;54:103104. doi: 10.1016/j.msard.2021.103104. Epub 2021 Jun 24.
7
Mitoxantrone: a review of its use in multiple sclerosis.米托蒽醌:其在多发性硬化症中的应用综述
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
8
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.一种用于评估疾病进展的医生完成式数字工具(多发性硬化症进展讨论工具):验证研究
J Med Internet Res. 2020 Feb 12;22(2):e16932. doi: 10.2196/16932.
9
Early clinical markers of aggressive multiple sclerosis.早期侵袭性多发性硬化的临床标志物。
Brain. 2020 May 1;143(5):1400-1413. doi: 10.1093/brain/awaa081.
10
Clinical Relevance of Multiparametric MRI Assessment of Cervical Cord Damage in Multiple Sclerosis.多参数 MRI 评估在多发性硬化症中对颈髓损伤的临床相关性。
Radiology. 2020 Sep;296(3):605-615. doi: 10.1148/radiol.2020200430. Epub 2020 Jun 23.

引用本文的文献

1
COVID-19 and the Pandemic-Related Aspects in Pediatric Demyelinating Disorders.COVID-19 与儿科脱髓鞘疾病相关的大流行方面。
Semin Pediatr Neurol. 2023 Jul;46:101055. doi: 10.1016/j.spen.2023.101055. Epub 2023 May 10.
2
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.基于疫苗的对 SARS-CoV-2 感染的临床保护和体液免疫反应:接受奥瑞珠单抗治疗的多发性硬化症患者的 1 年随访研究。
Front Immunol. 2022 Dec 23;13:1037214. doi: 10.3389/fimmu.2022.1037214. eCollection 2022.
3
Monkeypox in Multiple Sclerosis patients: Should we be alert?

本文引用的文献

1
COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis.伊朗多发性硬化症患者对 COVID-19 疫苗的犹豫。
Mult Scler Relat Disord. 2022 Apr;60:103723. doi: 10.1016/j.msard.2022.103723. Epub 2022 Mar 5.
2
Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis.抗 CD-20 治疗的多发性硬化症患者 COVID-19 的严重结局:系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Jan;57:103358. doi: 10.1016/j.msard.2021.103358. Epub 2021 Nov 5.
3
COVID-19 Severity Index: A predictive score for hospitalized patients.
多发性硬化症患者中的猴痘:我们应该警惕吗?
Mult Scler Relat Disord. 2022 Nov;67:104228. doi: 10.1016/j.msard.2022.104228. Epub 2022 Oct 8.
新冠病毒疾病严重程度指数:一种针对住院患者的预测评分
Med Intensiva (Engl Ed). 2022 Feb;46(2):98-101. doi: 10.1016/j.medine.2020.12.002. Epub 2021 Nov 30.
4
Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis.多发性硬化症患者发生重症 COVID-19 的风险因素:系统评价和荟萃分析。
Rev Neurol (Paris). 2022 Jan-Feb;178(1-2):121-128. doi: 10.1016/j.neurol.2021.10.003. Epub 2021 Nov 4.
5
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.COVID-19 严重程度在多发性硬化症中的表现:将数据置于具体情境中。
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1). doi: 10.1212/NXI.0000000000001105. Print 2022 Jan.
6
The MuSC-19 study: The Egyptian cohort.MuSC-19 研究:埃及队列。
Mult Scler Relat Disord. 2021 Nov;56:103324. doi: 10.1016/j.msard.2021.103324. Epub 2021 Oct 10.
7
Coronavirus disease 2019 in Latin American patients with multiple sclerosis.2019 年冠状病毒病在拉丁美洲多发性硬化症患者中的表现。
Mult Scler Relat Disord. 2021 Oct;55:103173. doi: 10.1016/j.msard.2021.103173. Epub 2021 Jul 25.
8
CANPT Score: A Tool to Predict Severe COVID-19 on Admission.CANPT评分:一种预测入院时重症COVID-19的工具。
Front Med (Lausanne). 2021 Feb 18;8:608107. doi: 10.3389/fmed.2021.608107. eCollection 2021.
9
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.疾病修正疗法与多发性硬化症中 2019 年冠状病毒病严重程度。
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
10
Risk factors for severe and critically ill COVID-19 patients: A review.COVID-19 患者重症和危重症的危险因素:综述。
Allergy. 2021 Feb;76(2):428-455. doi: 10.1111/all.14657. Epub 2020 Dec 4.